In a cooperative study of the Cancer and Acute Leukemia Group B, 27 evaluable patients with advanced malignant lymphomas were treated with 70 mg/m2 of cisdichlorodiammineplatinum(l1) (cis-platinum) once every three weeks. All patients had received extensive prior therapy. Partial remission was obtained in two of eight patients (25%) with Hodgkin's disease, for six and 40 weeks, and in five of 19 (26%) patients with non-Hodgkin's lymphoma, for a median duration of six weeks. The major toxic effects were profuse vomiting and, to a lesser degree, myelosuppression. Nephrotoxicity was easily controlled. Cis-platinum is an active agent in lymphoma and should merit incorporation into combination therapy for recently diagnosed disease. Cancer 48: 1927-1930, 198 1. ESPITE EXTENSIVE C L I N I C A L TRIALS recently per-D formed with cis-platinum, data on its efficacy in lymphoma have been limited.' Some activity in the lymphomas has been detected although the activity was found primarily in Phase I studies with varying doses used.* ' In August 1977, the New Agents Committee of the Cancer and Leukemia Group B (CALGB) began a Phase I1 trial of cis-platinum activity in lymphoma.
Reported herein are the results of this study.
Methods and Materials
Patient Selection
Patients with advanced histologically proven malignant lymphoma which was resistant to standard therapy A preliminary evaluation of this study was presented at the NCI Conference on Cis-platinum and Testicular Cancer. Washington D.